Latest Sarissa Capital Management LP Stock Portfolio
Sarissa Capital Management LP Performance:
2025 Q3: 11.68%YTD: -13.63%2024: -23.13%
Performance for 2025 Q3 is 11.68%, and YTD is -13.63%, and 2024 is -23.13%.
About Sarissa Capital Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Sarissa Capital Management LP reported an equity portfolio of $180.4 Millions as of 30 Sep, 2025.
The top stock holdings of Sarissa Capital Management LP are INVA, NBIX, CYTK. The fund has invested 28.5% of it's portfolio in INNOVIVA INC and 23.6% of portfolio in NEUROCRINE BIOSCIENCES INC.
The fund managers got completely rid off VOR BIOPHARMA INC (VOR) stocks. Sarissa Capital Management LP opened new stock positions in REGENERON PHARMACEUTICALS (REGN) and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to LANTHEUS HLDGS INC (LNTH).
The top stock holdings of Sarissa Capital Management LP are INVA, NBIX, CYTK. The fund has invested 28.5% of it's portfolio in INNOVIVA INC and 23.6% of portfolio in NEUROCRINE BIOSCIENCES INC.
The fund managers got completely rid off VOR BIOPHARMA INC (VOR) stocks. Sarissa Capital Management LP opened new stock positions in REGENERON PHARMACEUTICALS (REGN) and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to LANTHEUS HLDGS INC (LNTH).
Sarissa Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Sarissa Capital Management LP made a return of 11.68% in the last quarter. In trailing 12 months, it's portfolio return was -14.52%.
New Buys
| Ticker | $ Bought |
|---|---|
| regeneron pharmaceuticals | 2,355,910 |
| vor biopharma inc | 1,237,440 |
New stocks bought by Sarissa Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| lantheus hldgs inc | 88.52 |
Additions to existing portfolio by Sarissa Capital Management LP
Reductions
Sold off
| Ticker | $ Sold |
|---|---|
| vor biopharma inc | -822,986 |
Sarissa Capital Management LP got rid off the above stocks
Sector Distribution
Sarissa Capital Management LP has about 100% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 100 |
Market Cap. Distribution
Sarissa Capital Management LP has about 24.9% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 40 |
| LARGE-CAP | 24.9 |
| MID-CAP | 23.1 |
| MICRO-CAP | 12 |
Stocks belong to which Index?
About 65.1% of the stocks held by Sarissa Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 63.8 |
| Others | 34.9 |
| S&P 500 | 1.3 |
Sarissa Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Sarissa Capital Management LP
Sarissa Capital Management LP has 8 stocks in it's portfolio. INVA proved to be the most loss making stock for the portfolio. CYTK was the most profitable stock for Sarissa Capital Management LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AMRN | amarin corp plc | 11.28 | 1,242,530 | 20,352,600 | unchanged | 0.00 | ||
| CYTK | cytokinetics inc | 17.92 | 588,357 | 32,336,100 | unchanged | 0.00 | ||
| INVA | innoviva inc | 28.49 | 2,816,020 | 51,392,400 | unchanged | 0.00 | ||
| IRWD | ironwood pharmaceuticals inc | 11.56 | 15,919,400 | 20,854,500 | unchanged | 0.00 | ||
| LNTH | lantheus hldgs inc | 5.16 | 181,450 | 9,306,570 | added | 88.52 | ||
| NBIX | neurocrine biosciences inc | 23.59 | 303,151 | 42,556,300 | unchanged | 0.00 | ||
| REGN | regeneron pharmaceuticals | 1.31 | 4,190 | 2,355,910 | new | |||
| VOR | vor biopharma inc | 0.69 | 25,399 | 1,237,440 | new | |||
| VOR | vor biopharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||